Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.

What Was Tested

Researchers studied GLOW Blend (GHK-Cu + BPC-157 + TB-500) in this randomized controlled trial publication.

Zolbetuximab is a monoclonal antibody targeting claudin 18 isoform 2 (CLDN18.2) approved for first-line treatment of CLDN18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

Global, double-blind, phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials investigated zolbetuximab plus chemotherapy versus placebo plus chemotherapy in patients with CLDN18.2-positive, HER2-negative, LA unresectable or metastatic gastric or GEJ adenocarcinoma.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this GLOW Blend (GHK-Cu + BPC-157 + TB-500) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind GLOW Blend (GHK-Cu + BPC-157 + TB-500) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of GLOW Blend (GHK-Cu + BPC-157 + TB-500), giving a reference point.

The primary endpoint in both trials was progression-free survival (PFS); overall survival (OS) was a key secondary endpoint.

What Was Measured

PubMed files the paper under topics including Stomach Neoplasms, Adenocarcinoma, Esophagogastric Junction, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized and Claudins.

The authors tagged it with the keywords Zolbetuximab.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GLOW Blend (GHK-Cu + BPC-157 + TB-500).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association), a journal based in Japan.

More context: the GLOW Blend (GHK-Cu + BPC-157 + TB-500) compound page, all human trials.